PROCEDURES FOR SCIENTIFIC REVIEW AND SCIENTIFIC MONITORING: Cancer Protocol Committee and the Cancer Sciences Subcommittee Scientific Review Criteria The Cancer Protocol Committee is charged with the scientific peer review of all cancer-related therapeutic (agent or device) research protocols. All cancer-related protocols, regardless of sponsorship, must be approved by the CPC before final IRB approval will be granted. The Committee's evaluation of scientific merit of the proposed research includes consideration of the following areas Rationale of the proposed research and supporting preliminary data Scientific design Appropriateness of the eligibility criteria (including justification for inclusion of a pediatric population if applicable) Feasibility for completion (including potential accrual and competing studies) Risks and benefits as they relate to the scientific merit Biostatistical rigor The primary review emphasis is on the scientific merit of the proposed research. In granting approval of a therapeutic trial and access to the proposed subject population, the committee bases its decision on the level of scientific merit, Center priorities, and the feasibility for completion of the trial within a scientifically relevant period of time. The Committee also serves in an advisory capacity to the ORB on issues of research risk and informed consent. The adequacy of each of the areas enumerated above is judged in accordance with specific criteria which are enumerated on protocol review forms. The intent is to enhance the quality of clinical research by providing constructive criticism to the investigator proposing the research. In pursuit of this goal, guidelines for the writing of oncology protocols have been established, modeled after those of the NCI's, and are available to investigators (""""""""The Essential Elements of an Oncology Protocol""""""""). The process for the scientific monitoring of institutional protocols is done by the CPC in collaboration with the Scientific Monitoring Subcommittee. This is addressed below in the section entitled """"""""Scientific Monitoring.""""""""

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-33
Application #
7726637
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-01-01
Budget End
2007-12-31
Support Year
33
Fiscal Year
2007
Total Cost
$65,780
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408
Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2018) Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer. Mol Carcinog 57:216-224
Naqvi, Ibtehaj; Gunaratne, Ruwan; McDade, Jessica E et al. (2018) Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Mol Ther 26:1020-1031
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Gearhart-Serna, Larisa M; Jayasundara, Nishad; Tacam Jr, Moises et al. (2018) Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations. J Environ Public Health 2018:5610462
Bakthavatsalam, Subha; Sleeper, Mark L; Dharani, Azim et al. (2018) Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. Angew Chem Int Ed Engl 57:12780-12784
Dai, Ziwei; Mentch, Samantha J; Gao, Xia et al. (2018) Methionine metabolism influences genomic architecture and gene expression through H3K4me3 peak width. Nat Commun 9:1955
Powell Gray, Bethany; Kelly, Linsley; Ahrens, Douglas P et al. (2018) Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer. Proc Natl Acad Sci U S A 115:4761-4766

Showing the most recent 10 out of 513 publications